Open access · CC-BY
via OpenAlex
Metabolic reprogramming of pulmonary fibrosis
Jiaxin Li, Xiaoxuan Zhai, Xiao Sun, Shengchuan Cao, Qiuhuan Yuan, Jiali Wang
Frontiers in Pharmacology · 2022 · ▲ 55 citations
Chronic inflammation
Disabled macroautophagy
Partial reprogramming (OSK)
Cell culture / in vitro
Review
Abstract
Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that affects alveoli elasticity, which leading to higher rates of hospitalization and mortality worldwide. Pulmonary fibrosis is initiated by repetitive localized micro-damages of the alveolar epithelium, which subsequently triggers aberrant epithelial-fibroblast communication and myofibroblasts production in the extracellular matrix, resulting in massive extracellular matrix accumulation and interstitial remodeling. The major cell types responsible for pulmonary fibrosis are myofibroblasts, alveolar epithelial cells, macrophages, and endothelial cells. Recent studies have demonstrated that metabolic reprogramming or dysregulation of these cells exerts their profibrotic role via affecting pathological mechanisms such as autophagy(definition), apoptosis, aging, and inflammatory responses, which ultimately contributes to the development of pulmonary fibrosis. This review summarizes recent findings on metabolic reprogramming that occur in the aforementioned cells during pulmonary fibrosis, especially those associated with glucose, lipid, and amino acid metabolism, with the aim of identifying novel treatment targets for pulmonary fibrosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fphar.2022.1031890
- Canonical
- link ↗
- Fetched
- 2026-10-24 MST
Cite this
APA
Li, J., Zhai, X., Sun, X., Cao, S., Yuan, Q., & Wang, J. (2022). Metabolic reprogramming of pulmonary fibrosis. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2022.1031890
Vancouver
Li J, Zhai X, Sun X, Cao S, Yuan Q, Wang J. Metabolic reprogramming of pulmonary fibrosis. Frontiers in Pharmacology. 2022. doi:10.3389/fphar.2022.1031890.
BibTeX
@article{jiaxin2022Metabo,
title = {Metabolic reprogramming of pulmonary fibrosis},
author = {Jiaxin Li and Xiaoxuan Zhai and Xiao Sun and Shengchuan Cao and Qiuhuan Yuan and Jiali Wang},
journal = {Frontiers in Pharmacology},
year = {2022},
doi = {10.3389/fphar.2022.1031890},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Tissue Microenvironment Reports 2021
Open access · CC-BY
Extracellular Matrix Remodeling in Chronic Liver Disease
Medicina 2019
Open access · CC-BY
Epithelial–Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Frontiers in Cell and Developmental Biology 2022
Open access · CC-BY
Alveolar type 2 epithelial cell senescence and radiation-induced pulmonary fibrosis
eLife 2018
Open access · CC-BY
Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres
Journal of Thoracic Disease 2022
Open access · CC-BY
Molecular mechanisms of alveolar epithelial cell senescence and idiopathic pulmonary fibrosis: a narrative review
The Journal of Pathology 2003
Open access · OA